Previous 10 | Next 10 |
2024-03-21 17:19:19 ET More on Armata Pharmaceuticals Armata enters $35M credit agreement with Innoviva Seeking Alpha’s Quant Rating on Armata Pharmaceuticals Historical earnings data for Armata Pharmaceuticals Financial information for Armata Pharmace...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology com...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 20...
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit PR Newswire LOS ANGELES , Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on...
2023-11-14 17:11:39 ET More on Armata Pharmaceuticals Seeking Alpha’s Quant Rating on Armata Pharmaceuticals Historical earnings data for Armata Pharmaceuticals Financial information for Armata Pharmaceuticals For further details see: Armata Pharma...
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES , Nov. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pa...
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference PR Newswire LOS ANGELES , Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or t...
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 PR Newswire LOS ANGELES , Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pa...
2023-10-09 13:48:03 ET Summary Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it receives from Glaxo Group Limited. There has been ...
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus PR Newswire Initiation of the Phase 2a portion follows DRC review of positive safety and tolerabilit...
News, Short Squeeze, Breakout and More Instantly...
Armata Pharmaceuticals Inc. Company Name:
ARMP Stock Symbol:
NYSE Market:
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update PR Newswire LOS ANGELES , May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology com...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 20...